LON:AGYAllergy Therapeutics Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 14 0.00 (0.00 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range 13.77Now: GBX 14▼ 14.5050-Day Range 10.75MA: GBX 12.08▼ 14.4552-Week Range 0.12Now: GBX 14▼ 14.50Volume160,968 shsAverage Volume167,682 shsMarket Capitalization£89.06 millionP/E Ratio11.67Dividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil. It also develops clinical pipeline products that include vaccines for grass, tree, and house dust mite, as well as a peanut allergy vaccine that is in pre-clinical stage. The company primarily sells its products in European countries. Allergy Therapeutics plc was founded in 1934 and is based in Worthing, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Allergy Therapeutics. Previous Next 3.2 Community Rank Outperform VotesAllergy Therapeutics has received 361 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAllergy Therapeutics has received 203 “underperform” votes. (Add your “underperform” vote.)Community SentimentAllergy Therapeutics has received 64.01% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Allergy Therapeutics and other stocks. Vote “Outperform” if you believe AGY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AGY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAllergy Therapeutics does not currently pay a dividend.Dividend GrowthAllergy Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allergy Therapeutics insiders have not sold or bought any company stock. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Allergy Therapeutics are expected to grow in the coming year, from GBX (1.35) to GBX 0 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allergy Therapeutics is 11.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 15.16.Price to Earnings Ratio vs. SectorThe P/E ratio of Allergy Therapeutics is 11.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.24.Price to Book Value per Share RatioAllergy Therapeutics has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.02 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical Current SymbolLON:AGY Previous Symbol CUSIPN/A CIKN/A Webwww.allergytherapeutics.com Phone+44-1903-844700Debt Debt-to-Equity Ratio21.42 Current Ratio3.83 Quick Ratio3.23Price-To-Earnings Trailing P/E Ratio11.67 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£77.48 million Price / Sales1.15 Cash FlowGBX 6.55 per share Price / Cash Flow2.14 Book ValueGBX 8 per share Price / Book1.75Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees500 Outstanding Shares636,169,024Market Cap£89.06 million Next Earnings DateN/A OptionableNot Optionable LSE:AGY Rates by TradingView Receive AGY News and Ratings via Email Sign-up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter. Allergy Therapeutics (LON:AGY) Frequently Asked Questions How has Allergy Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Allergy Therapeutics' stock was trading at GBX 9.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGY shares have increased by 51.4% and is now trading at GBX 14. View which stocks have been most impacted by Coronavirus. How were Allergy Therapeutics' earnings last quarter? Allergy Therapeutics plc (LON:AGY) posted its earnings results on Wednesday, March, 4th. The company reported $2.40 EPS for the quarter. View Allergy Therapeutics' earnings history. Has Allergy Therapeutics been receiving favorable news coverage? News headlines about AGY stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Allergy Therapeutics earned a daily sentiment score of -1.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Allergy Therapeutics. Who are some of Allergy Therapeutics' key competitors? Some companies that are related to Allergy Therapeutics include Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), NanoViricides (NNVC), Trilogy International Partners (TRL), Recce Pharmaceuticals (RCE), Futura Medical (FUM), Vita Life Sciences (VLS), Pharmaxis (PXS), Antisense Therapeutics (ANP), China Pharma (CPHI), Avivagen (VIV), Sareum (SAR), Patrys (PAB), Cathay International (CTI) and N4 Pharma (N4P). View all competitors. What other stocks do shareholders of Allergy Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allergy Therapeutics investors own include Relypsa (RLYP), Royalty Pharma (RPRX), Spectrum Pharmaceuticals (SPPI), Verastem (VSTM), ADOCIA/S (ADOCY), Berkeley Energia (BKY), Barfresh Food Group (BRFH), Burford Capital (BUR), Dechra Pharmaceuticals (DPH) and Direxion Daily Gold Miners Index Bear 2x Shares (DUST). Who are Allergy Therapeutics' key executives? Allergy Therapeutics' management team includes the following people: Mr. Manuel Llobet, CEO & Exec. Director (Age 55)Mr. Nicolas Alexander Ulrich Wykeman, CFO & Director (Age 54)Ms. Beverly Lees, Group Operations DirectorDr. Murray Skinner, Chief Scientific OfficerMr. Santiago Puig, Bus. Devel. Director What is Allergy Therapeutics' stock symbol? Allergy Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "AGY." How do I buy shares of Allergy Therapeutics? Shares of AGY and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Allergy Therapeutics' stock price today? One share of AGY stock can currently be purchased for approximately GBX 14. How big of a company is Allergy Therapeutics? Allergy Therapeutics has a market capitalization of £89.06 million and generates £77.48 million in revenue each year. Allergy Therapeutics employs 500 workers across the globe. What is Allergy Therapeutics' official website? The official website for Allergy Therapeutics is www.allergytherapeutics.com. How can I contact Allergy Therapeutics? Allergy Therapeutics' mailing address is Dominion Way, WORTHING, BN14 8SA, United Kingdom. The company can be reached via phone at +44-1903-844700. This page was last updated on 7/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
